- Markets
- Healthcare
- BAJAJHCARE
BAJAJHCARE
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Bajaj Healthcare hits record high as seizure drug trial gets regulatory nod
** Shares of Bajaj Healthcare BAJH.NS rise as much as 10.3% to hit record high at 745 rupees
** The pharmaceutical co says its has secured SEC-CDSCO nod for Phase III clinical trials of anti-seizure medication Cenobamate tablets
** Phase III clinical trials are the final stage of drug development before regulatory approval - BAJH
** Stock on track for a third consecutive session of gain, if trend holds
** Stock is witnessing its most active trading session since January 29, with more than 1.3 mln shares changing hands, 3.3x of 30-day avg
** Stock last up 6%, taking YTD gains to 25%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of Bajaj Healthcare BAJH.NS rise as much as 10.3% to hit record high at 745 rupees
** The pharmaceutical co says its has secured SEC-CDSCO nod for Phase III clinical trials of anti-seizure medication Cenobamate tablets
** Phase III clinical trials are the final stage of drug development before regulatory approval - BAJH
** Stock on track for a third consecutive session of gain, if trend holds
** Stock is witnessing its most active trading session since January 29, with more than 1.3 mln shares changing hands, 3.3x of 30-day avg
** Stock last up 6%, taking YTD gains to 25%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
Bajaj Healthcare Gets Approval From DCGI To Manufacture API And Drug Formulation Of Pimavanserin
Jan 30 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
GETS APPROVAL FROM DCGI TO MANUFACTURE API AND DRUG FORMULATION OF PIMAVANSERIN
Source text: [ID:]
Further company coverage: BAJH.NS
(([email protected];;))
Jan 30 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
GETS APPROVAL FROM DCGI TO MANUFACTURE API AND DRUG FORMULATION OF PIMAVANSERIN
Source text: [ID:]
Further company coverage: BAJH.NS
(([email protected];;))
Bajaj Healthcare Enters Into CDMO Contract With UK/ EU Based Cos
Dec 9 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
BAJAJ HEALTHCARE LTD - ENTERING INTO A CDMO CONTRACT WITH UK/ EU BASED COS
BAJAJ HEALTHCARE LTD - CONTRACTS FOR 15 NEW APIS
Source text: ID:nNSE3gW5bF
Further company coverage: BAJH.NS
(([email protected];))
Dec 9 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
BAJAJ HEALTHCARE LTD - ENTERING INTO A CDMO CONTRACT WITH UK/ EU BASED COS
BAJAJ HEALTHCARE LTD - CONTRACTS FOR 15 NEW APIS
Source text: ID:nNSE3gW5bF
Further company coverage: BAJH.NS
(([email protected];))
Bajaj Healthcare's API Manufacturing Site At Vadodara Gets Approval From TGA Australia
Dec 6 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVAL FROM THERAPEUTIC GOODS ADMINISTRATION (TGA), AUSTRALIA
CO'S API MANUFACTURING SITE AT VADODARA GETS APPROVAL FROM TGA AUSTRALIA
VADODARA SITE HAS ALREADY RECEIVED APPROVAL FROM USFDA AND EU
TGA APPROVAL VALID FOR 24 MONTHS
Source text: ID:nBSE374MtW
Further company coverage: BAJH.NS
(([email protected];;))
Dec 6 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVAL FROM THERAPEUTIC GOODS ADMINISTRATION (TGA), AUSTRALIA
CO'S API MANUFACTURING SITE AT VADODARA GETS APPROVAL FROM TGA AUSTRALIA
VADODARA SITE HAS ALREADY RECEIVED APPROVAL FROM USFDA AND EU
TGA APPROVAL VALID FOR 24 MONTHS
Source text: ID:nBSE374MtW
Further company coverage: BAJH.NS
(([email protected];;))
Bajaj Healthcare Enters Into Development,Supply Agreement For API
Sept 23 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
ENTERING INTO DEVELOPMENT AND SUPPLY AGREEMENT FOR API
ENTERING INTO DEVELOPMENT AND SUPPLY AGREEMENT FOR API WITH EUROPEAN ENTITY
API AFTER DEVELOPMENT WILL BE BY EU PARTNER TO CARRY OUT CLINICAL TRIALS
BASED ON TRIAL OUTCOMES, SUPPLIES WILL BE DONE FROM CO’S FACILITY AT SAVLI
Source text for Eikon: ID:nBSE9nmnTV
Further company coverage: BAJH.NS
(([email protected];;))
Sept 23 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
ENTERING INTO DEVELOPMENT AND SUPPLY AGREEMENT FOR API
ENTERING INTO DEVELOPMENT AND SUPPLY AGREEMENT FOR API WITH EUROPEAN ENTITY
API AFTER DEVELOPMENT WILL BE BY EU PARTNER TO CARRY OUT CLINICAL TRIALS
BASED ON TRIAL OUTCOMES, SUPPLIES WILL BE DONE FROM CO’S FACILITY AT SAVLI
Source text for Eikon: ID:nBSE9nmnTV
Further company coverage: BAJH.NS
(([email protected];;))
Bajaj Healthcare To Consider Raising Of Funds
July 5 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
TO CONSIDER RAISING OF FUNDS
Further company coverage: BAJH.NS
(([email protected];))
July 5 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
TO CONSIDER RAISING OF FUNDS
Further company coverage: BAJH.NS
(([email protected];))
Bajaj Healthcare Appoints Dayashankar Patel As CFO
May 6 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPOINTS DAYASHANKAR PATEL AS CFO
Source text for Eikon: ID:nBSE5TVcLJ
Further company coverage: BAJH.NS
(([email protected];))
May 6 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPOINTS DAYASHANKAR PATEL AS CFO
Source text for Eikon: ID:nBSE5TVcLJ
Further company coverage: BAJH.NS
(([email protected];))
India's Bajaj Healthcare rises on API supply deal
** Shares of Bajaj Healthcare BAJH.NS up 15% in heavy vols
** Pharma co enters into agreement with UK/EU-based customers to supply 15 Active Pharmaceutical Ingredients
** BAJH set for best day in six months, if trend holds
** Stock sees most active day in 2024, trading vols 18X the 30-day avg
** Session's gains help BAJH turn green for the month
** BAJH up ~11% in February, after falling ~11% in January
(Reporting by Nishit Navin in Bengaluru)
(([email protected];))
** Shares of Bajaj Healthcare BAJH.NS up 15% in heavy vols
** Pharma co enters into agreement with UK/EU-based customers to supply 15 Active Pharmaceutical Ingredients
** BAJH set for best day in six months, if trend holds
** Stock sees most active day in 2024, trading vols 18X the 30-day avg
** Session's gains help BAJH turn green for the month
** BAJH up ~11% in February, after falling ~11% in January
(Reporting by Nishit Navin in Bengaluru)
(([email protected];))
Bajaj Healthcare Price Erosion Of Major APIs That Co Deals With Reduced Topline
Feb 9 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
BAJAJ HEALTHCARE LTD - PRICE EROSION OF MAJOR APIS THAT CO DEALS WITH REDUCED TOPLINE
BAJAJ HEALTHCARE LTD - BELIEVE HEADWINDS TO BE TRANSITORY IN NATURE
BAJAJ HEALTHCARE LTD - OPTIMISTIC OF REGAINING TARGETED BUSINESS IN THE COMING QUARTERS
BAJAJ HEALTHCARE LTD - VADODARA PLANT WILL LEAD TO SURGE IN REVENUE, MARGINS FROM NEXT ONE/TWO QTRS ONWARDS
Source text for Eikon: ID:nNSE9khx2T
Further company coverage: BAJH.NS
(([email protected];;))
Feb 9 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
BAJAJ HEALTHCARE LTD - PRICE EROSION OF MAJOR APIS THAT CO DEALS WITH REDUCED TOPLINE
BAJAJ HEALTHCARE LTD - BELIEVE HEADWINDS TO BE TRANSITORY IN NATURE
BAJAJ HEALTHCARE LTD - OPTIMISTIC OF REGAINING TARGETED BUSINESS IN THE COMING QUARTERS
BAJAJ HEALTHCARE LTD - VADODARA PLANT WILL LEAD TO SURGE IN REVENUE, MARGINS FROM NEXT ONE/TWO QTRS ONWARDS
Source text for Eikon: ID:nNSE9khx2T
Further company coverage: BAJH.NS
(([email protected];;))
Bajaj Healthcare CFO Rupesh Nikam Resigns
Dec 1 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
CFO RUPESH NIKAM RESIGNS
Further company coverage: BAJH.NS
(([email protected];))
Dec 1 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
CFO RUPESH NIKAM RESIGNS
Further company coverage: BAJH.NS
(([email protected];))
India's Bajaj Healthcare up on retaining growth forecast
** Shares of Bajaj Healthcare BAJH.NS rise as much as 7.4% to 406.5 rupees, biggest intraday gain since Sept. 22
** Co says it expects demand to improve in coming quarters
** Management confident of continued growth in EBITDA margin for 2HFY24 due to focus on more value added products, increase in exports and successful commissioning of Alkaloid Extraction Plant
** More than 394,391 shares traded by 02:10 p.m. IST, 1.4x the 30-day avg
** Stock currently up 4.6% trimming YTD losses to 10%
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Bajaj Healthcare BAJH.NS rise as much as 7.4% to 406.5 rupees, biggest intraday gain since Sept. 22
** Co says it expects demand to improve in coming quarters
** Management confident of continued growth in EBITDA margin for 2HFY24 due to focus on more value added products, increase in exports and successful commissioning of Alkaloid Extraction Plant
** More than 394,391 shares traded by 02:10 p.m. IST, 1.4x the 30-day avg
** Stock currently up 4.6% trimming YTD losses to 10%
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Bajaj Healthcare Commissions Alkaloid Extraction Plant In Vadodara
Oct 18 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
SUCCESSFUL COMMISSIONING OF ALKALOID EXTRACTION PLANT IN VADODARA
Source text for Eikon: ID:nNSETrj6c
Further company coverage: BAJH.NS
(([email protected];))
Oct 18 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
SUCCESSFUL COMMISSIONING OF ALKALOID EXTRACTION PLANT IN VADODARA
Source text for Eikon: ID:nNSETrj6c
Further company coverage: BAJH.NS
(([email protected];))
India's Bajaj Healthcare jumps on FDA report for Vadodara plant
** Shares of Bajaj Healthcare BAJH.NS rise as much as 8.2% to 446 rupees, highest since Jan. 4
** Stock set to rise for a second straight session if gains hold
** Co on Wednesday said it received U.S. FDA's establishment inspection report for its manufacturing site in Vadodara
** EIR had zero 483 observations, co added
** More than 970,000 shares change hands by 10:21 a.m. IST, 3.1x 30-day avg
** Volume above 800,000 for fourth session this month
** Stock up 2.6% as of 10:21 a.m. IST, trimming YTD losses to 4.9%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
** Shares of Bajaj Healthcare BAJH.NS rise as much as 8.2% to 446 rupees, highest since Jan. 4
** Stock set to rise for a second straight session if gains hold
** Co on Wednesday said it received U.S. FDA's establishment inspection report for its manufacturing site in Vadodara
** EIR had zero 483 observations, co added
** More than 970,000 shares change hands by 10:21 a.m. IST, 3.1x 30-day avg
** Volume above 800,000 for fourth session this month
** Stock up 2.6% as of 10:21 a.m. IST, trimming YTD losses to 4.9%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
India's Bajaj Healthcare up on sale of units
** Shares of Bajaj Healthcare BAJH.NS rise as much as 7% to 323.6 rupees, highest since June 16
** Co on Wednesday approved sale of two plots in Maharashtra and one in Gujarat
** Facilities closed due to delay in getting various regulatory approvals and co being unable to amend processes for the products already manufactured in said units
** Co on track for second consecutive session of gains, if trends stand
** More than 85,909 shares change hands by 09:30 a.m. IST vs 1.2x 30-day avg of 73,546 shares
** Stock down 31.9% YTD up to last close
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Bajaj Healthcare BAJH.NS rise as much as 7% to 323.6 rupees, highest since June 16
** Co on Wednesday approved sale of two plots in Maharashtra and one in Gujarat
** Facilities closed due to delay in getting various regulatory approvals and co being unable to amend processes for the products already manufactured in said units
** Co on track for second consecutive session of gains, if trends stand
** More than 85,909 shares change hands by 09:30 a.m. IST vs 1.2x 30-day avg of 73,546 shares
** Stock down 31.9% YTD up to last close
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Bajaj Healthcare Approves Sale Of 2 Plots In Maharashtra And One In Gujarat
June 28 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVED SALE OF 2 PLOTS IN MAHARASHTRA AND ONE IN GUJARAT
Source text for Eikon: ID:nNSEM155T
Further company coverage: BAJH.NS
(([email protected];))
June 28 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVED SALE OF 2 PLOTS IN MAHARASHTRA AND ONE IN GUJARAT
Source text for Eikon: ID:nNSEM155T
Further company coverage: BAJH.NS
(([email protected];))
India's Bajaj Healthcare March-Quarter Profit Falls
May 30 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
INDIA'S BAJAJ HEALTHCARE LTD MARCH-QUARTER PROFIT 35.9 MILLION RUPEES VERSUS PROFIT 174.7 MILLION RUPEES
BAJAJ HEALTHCARE LTD MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.76 BILLION RUPEES
BAJAJ HEALTHCARE LTD - DIVIDEND 1 RUPEE PER SHARE
Source text for Eikon: ID:nBSE6BYSPC
Further company coverage: BAJH.NS
(([email protected];))
May 30 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
INDIA'S BAJAJ HEALTHCARE LTD MARCH-QUARTER PROFIT 35.9 MILLION RUPEES VERSUS PROFIT 174.7 MILLION RUPEES
BAJAJ HEALTHCARE LTD MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.76 BILLION RUPEES
BAJAJ HEALTHCARE LTD - DIVIDEND 1 RUPEE PER SHARE
Source text for Eikon: ID:nBSE6BYSPC
Further company coverage: BAJH.NS
(([email protected];))
Bajaj Healthcare Approved Re-Appointment Of Sajankumar Bajaj As Chairman And Managing Director
April 18 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVED RE-APPOINTMENT OF SAJANKUMAR BAJAJ AS CHAIRMAN AND MANAGING DIRECTOR
RE-APPOINTS ANIL JAIN AS MANAGING DIRECTOR
Source text for Eikon: ID:nBSE5XlRX7
Further company coverage: BAJH.NS
(([email protected];))
April 18 (Reuters) - Bajaj Healthcare Ltd BAJH.NS:
APPROVED RE-APPOINTMENT OF SAJANKUMAR BAJAJ AS CHAIRMAN AND MANAGING DIRECTOR
RE-APPOINTS ANIL JAIN AS MANAGING DIRECTOR
Source text for Eikon: ID:nBSE5XlRX7
Further company coverage: BAJH.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Split
Dividend
Bonus
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Bajaj Healthcare do?
Bajaj Healthcare Ltd specializes in producing Amino Acids, Nutritional Supplements, and Active Pharmaceutical Ingredients for Pharmaceutical, Nutraceuticals, and Food industries, offering a wide range of products.
Who are the competitors of Bajaj Healthcare?
Bajaj Healthcare major competitors are IOL Chem & Pharma, SMS Pharmaceuticals, Hester Biosciences, Solara Active Pharma, Themis Medicare, Shree Ganesh Remed., Kopran. Market Cap of Bajaj Healthcare is ₹1,942 Crs. While the median market cap of its peers are ₹1,512 Crs.
Is Bajaj Healthcare financially stable compared to its competitors?
Bajaj Healthcare seems to be less financially stable compared to its competitors. Altman Z score of Bajaj Healthcare is 3.82 and is ranked 7 out of its 8 competitors.
Does Bajaj Healthcare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Bajaj Healthcare latest dividend payout ratio is 4.34% and 3yr average dividend payout ratio is 5.07%
How has Bajaj Healthcare allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Bajaj Healthcare balance sheet?
Balance sheet of Bajaj Healthcare is strong. But short term working capital might become an issue for this company.
Is the profitablity of Bajaj Healthcare improving?
The profit is oscillating. The profit of Bajaj Healthcare is -₹1.61 Crs for TTM, -₹83.79 Crs for Mar 2024 and ₹43.02 Crs for Mar 2023.
Is the debt of Bajaj Healthcare increasing or decreasing?
The debt of Bajaj Healthcare is decreasing. Latest debt of Bajaj Healthcare is ₹182 Crs as of Sep-24. This is less than Mar-24 when it was ₹326 Crs.
Is Bajaj Healthcare stock expensive?
Bajaj Healthcare is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Bajaj Healthcare is 0.0, while 3 year average PE is 14.66. Also latest EV/EBITDA of Bajaj Healthcare is 24.5 while 3yr average is 13.01.
Has the share price of Bajaj Healthcare grown faster than its competition?
Bajaj Healthcare has given better returns compared to its competitors. Bajaj Healthcare has grown at ~34.15% over the last 6yrs while peers have grown at a median rate of 23.07%
Is the promoter bullish about Bajaj Healthcare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Bajaj Healthcare is 59.19% and last quarter promoter holding is 59.19%.
Are mutual funds buying/selling Bajaj Healthcare?
The mutual fund holding of Bajaj Healthcare is stable. The current mutual fund holding in Bajaj Healthcare is 1.64% while previous quarter holding is 1.64%.